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Abstract 
Background and aims 
The incidence and mortality from end-stage liver disease is increasing, with a 
minority eligible for liver transplantation. Ascites is the commonest 
complication of end-stage liver disease and large volume paracentesis (LVP) 
the accepted management strategy where refractory to medical treatment. In 
malignant ascites, permanent indwelling peritoneal catheters (PIPC) are an 
established palliative intervention. The aims are to describe available data 
using permanent indwelling peritoneal catheters in refractory ascites due to 
end-stage liver disease. 
Methods 
Using systematic review methodology, databases were searched (MEDLINE, 
EMBASE, CINAHL [The Cumulative Index to Nursing and Allied Health 
Literature], Google Scholar and Cochrane Database of Systematic Reviews 
from inception-March 2018), for studies combining ascites and palliative care. 
Inclusion and exclusion criteria were applied to results.  
Results 
Following initial and updated searches, 225 studies were identified for full text 
review, 18 were eligible for final analysis. The studies displayed heterogeneity 
in design, reported on different indwelling catheters and were overall of low 
quality. Only one pilot randomised controlled trial was identified, of PIPC 
versus LVP, recruiting one patient into each arm. Technical insertion success 
was 100%, with low rates of non-infectious complications (<12%), none life 
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threatening. Rates of bacterial peritonitis were not unacceptably high (12.7%), 
considering this was an end-stage liver disease population and only a minority 
utilising long-term prophylactic antibiotics. Only one study attempted quality-
of-life assessments; none addressed potential health economic benefits. 
Conclusions 
Despite lack of well-designed studies, preliminary data suggests low 
significant complication rates; however safety and efficacy of permanent 
indwelling peritoneal catheters in end-stage liver disease remains to be 
confirmed. Further prospective randomised controlled trials are warranted, 
potentially translating permanent indwelling peritoneal catheters into improved 
palliative care in end-stage liver disease. 
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Lay summary 
The standard treatment for patients with advanced liver scarring (cirrhosis) 
and medically untreatable abdominal fluid (ascites) is repeated hospitalisation 
for drainage (large volume paracentesis, LVP). This article reports on the 
current available evidence of using long-term abdominal drains (PIPC) which 
remain permanently in the abdomen and reduce the need for repeated 
hospitalisation. We found low rates of serious complications. However, safety 
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and effectiveness of PIPC in people with cirrhosis needs to be confirmed by 
further research.   
 
 
 
 7 
Introduction 
In the UK over the last 40 years, the incidence of chronic liver disease (CLD) 
and related mortality has increased dramatically.1 The complexity of palliative 
and end of life care (EoLC) in end-stage liver disease (ESLD) means the 
majority die in hospital,2 with minimal specialist palliative care provided in 
hospice or community settings.3  
Ascites develops in most (approximately 90%) with ESLD.4–6 Refractory 
ascites (RA) either represents diuretic resistance (lack of response); or 
diuretic intolerance (development of complications precluding further use).4,7 
Upon developing RA, median survival is 6 months,4 mandating liver 
transplantation (LT) consideration. Only a minority with ESLD (1.3%-12%)8,5,9 
undergo LT, due to ongoing substance misuse, alcohol recidivism, co-
morbidity and in the context of a limited donor pool.5,8–11 Additionally, such 
individuals are often also not deemed to be candidates for TIPS or the 
ALFApump due to advanced disease stage. 
Individuals with RA who are not LT candidates are therefore considered to be 
in a palliative phase, often dominated by the management of ascites as the 
commonest complication. The most accepted palliative intervention is large 
volume paracentesis (LVP), mandating repeated hospital attendance for 
insertion of a temporary drain.4  
RA development has a major impact on quality of life (QoL) due to 
considerable symptom burden including abdominal distention, dyspnoea and 
poor appetite.12 Frequent LVPs offer only limited relief as ascites re-
accumulates.12  
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Permanent indwelling peritoneal catheters (PIPC) are an accepted strategy in 
the palliation of recurrent malignant ascites.13,14 Two PIPC are commercially 
available, PleurX™ and Rocket® Medical.14,15 A National Institute for Health 
and Care Excellence (NICE) technology appraisal reported low device-related 
infections (5.8%), 100% technical success and improvements in symptom 
control.13  
There has been reluctance towards PIPC in ESLD due to concerns mainly 
regarding infection risk, specifically peritonitis. 
Patients and methods 
A search strategy was used, based on tables 4 and 5. The aim of this 
systematic review is to “identify and describe the current evidence available 
on the use of PIPC in RA due to ESLD”. The PICOS structure (participants, 
interventions, comparators, outcomes, and study design) was used as 
described by PRISMA (Preferred Reporting Items for Systematic reviews and 
Meta-Analyses).16  
Participants  
RA in the context of ESLD. 
Intervention  
PIPC in the palliative management of RA. 
Comparisons  
Not relevant as no known comparison studies. 
Outcomes  
Including:  
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- Numbers of participants with ESLD   
- Adverse events (AE) and complications, particularly infection related  
- Use of prophylactic antibiotics  
- Place of subsequent drainage  
- Duration PIPC remained in situ 
- Specialist palliative care support 
- Participant survival  following PIPC insertion  
- Quality of life 
- Health economics 
Study design  
Randomised controlled trials, prospective and retrospective cohort studies as 
well as case series were included.  
Search strategy (see appendices) 
A systematic electronic search was performed using: MEDLINE, EMBASE, 
CINAHL (The Cumulative Index to Nursing and Allied Health Literature), 
Google Scholar and the Cochrane Database of Systematic Reviews. 
Platforms used to access the databases were the Healthcare Databases 
Advanced Search (HDAS) and OVID. The initial search was undertaken in 
December 2015 (Table 1).  
Table 1 
The search themes related to ascites and palliative care, these were 
subsequently combined (Table 2). Search results were limited to English 
language. All levels of evidence were included due to paucity of available 
data. 
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MeSH headings and keyword search terms were constructed from pilot 
searches. References were exported into Endnote™ web basic reference 
manager. 
Hand searching of reference lists in relevant manuscripts was performed. 
Online portals for major journals including Hepatology (American Association 
for the Study of Liver Diseases journal) and the Journal of Hepatology (The 
European Association for the Study of the Liver (EASL) journal) were 
searched for relevant publications and conference abstracts.  
The search was updated on 13th March 2018 using the same methodology 
and search strategies. Articles were selected using the original exclusion and 
inclusion criteria (Table 3).  
Table 2 
 
Keywords and MeSH terms  
 
Table 3 
 
Eligibility criteria 
 
Study selection 
LM reviewed titles and abstracts of identified manuscripts for relevance and 
screened full texts applying exclusion criteria. AH independently reviewed a 
selection.  
Quality assessment 
The Newcastle-Ottawa Scale (NOS), developed to assess the quality of non-
randomised studies including cohort studies, was used as a tool to assess 
those meeting inclusion criteria.17  
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Data extraction  
LM designed a data extraction form which was applied to selected studies by 
LM and AH independently, with inconsistencies reviewed by SV.  
Statistical analysis 
Studies identified for full analysis were heterogeneous in design, therefore a 
descriptive approach was undertaken.  
Results 
The database search returned 11,043 results. A screen for duplicate results 
performed using Endnote™ resulted in 6634 being removed. A further 4230 
were removed on the basis of: duplications not initially detected and exclusion 
criteria. Five full texts were unavailable from other UK libraries, however the 
titles met exclusion criteria. Full texts for the remaining 174 were reviewed.  
Citations were also identified through hand searching of journals, conference 
abstracts, reference lists of relevant manuscripts and those made known to 
the authors, yielding a further 51. In total, 225 studies were identified for full 
text review; 18 meeting full inclusion criteria for final analysis. (Figure 1) 
Study characteristics 
Of the final 18 studies included, one was planned as a pilot randomised 
controlled trial of PIPC versus LVP but only recruited one patient into each 
arm.18 Three were prospective19–21 and seven retrospective cohort studies;22-
28 one retrospective cohort study with matched controls;29 five were case 
series30-34 and one case report.35 Of these, 12 studies were available as full 
manuscripts18-21,23,24,26,28,29,32,34,35 and six as conference abstracts.22,25,27,30,31,33  
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Ten studies reported solely on RA due to cirrhosis;18,21,22,24,27,30-32,34,35 of 
these, two were cohorts including both ascites and hepatic 
hydrothoracies.22,27 These studies were not excluded due to the paucity of 
studies identified, though those with only hepatic hydrothoracies were 
excluded. The remaining eight studies described heterogeneous 
groups,19,20,23,25,26,28,29,33 including ascites due to cirrhosis, malignancy and 
other aetiologies with one reporting on both abdominal and pleural indwelling 
catheters.19 
Due to the small numbers identified, studies including both CLD and non-CLD 
aetiologies for ascites were not excluded. Studies without any participants 
with CLD as an aetiology were excluded.  
Patient characteristics 
Across all studies, 176 patients with refractory abdominal ascites due to 
cirrhosis were described. Separate studies independently reported on 
between one to 33 patients from this group. Cases of hepatic hydrothoracies 
which were described along with abdominal ascites,22,27 have not been 
included in the final analyses.  
Baseline liver disease severity scores were reported inconsistently; mean 
Model of End Stage Liver Disease (MELD) ranging from 10 to 22 and/or 
Child-Pugh B or C where reported.20-22,24,25,27,28,29,32,34 The remaining eight 
studies did not report severity scores.18,19,23,26,30,31,33,35  
Table 4 summarises the studies. 
Table 4 
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Quality 
The NOS, converting scores to the Agency for Healthcare Research and 
Quality standards of good, fair and poor;17 rated 17 studies as ‘poor’, since 
none scored points in the comparison domain. The final study scored 8 as 
was a well designed pilot randomised controlled trial of tunnelled peritoneal 
dialysis catheters versus LVP, however it could not be rated higher than ‘fair’ 
due to only two patients being enrolled, one to each arm, the outcomes 
therefore being significantly limited.18 
Type of indwelling catheter 
All included studies reported on permanent indwelling devices; permanent 
indwelling (tunnelled) peritoneal catheters in twelve studies (both PleurX™ 
and Rocket®),21-27,29-32,35 permanent subcutaneous port with intra-abdominal 
catheter (three studies)19,20,34 and permanent tunnelled peritoneal dialysis 
catheters (three studies).18,28,33 
Procedural insertion and success  
There was a 100% technical success rate for insertion of catheters in ESLD; 
being inserted by interventional radiologists in eight studies,19,20,22,23,26,27,31,34 
six stating insertion was performed under ultrasound guidance.19–21,23,26,34 
Three studies stated drainage catheters were inserted with ultrasound 
guidance but not by whom.21,24,35 Catheters were inserted by interventional 
nephrologists in two studies,18,28 one stating under ultrasound and 
fluoroscopic guidance.28 In a further two, catheters were inserted by 
consultant physicians/gastroenterologists under ultrasound guidance.25,32 Two 
studies did not report on insertion methods;21,30 one study reported catheters 
were inserted by trained physicians using X-ray guidance,29 and one drainage 
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catheter was inserted surgically (Tenckhoff catheter)33 (Table 4). There were 
no device related deaths.   
Antibiotic prophylaxis 
Nine studies used peri-procedural antibiotics for initial indwelling catheter 
insertion;18–21,23,25,28,29,34 six of these did not use further ongoing long-term 
prophylactic antibiotics,18-20,23,28,34  two used prophylaxis in limited cases.21,29 
Cephalosporins were used for peri-procedural prophylaxis in six 
studies,19,20,23,25,29,34 with one using Metronidazole in addition,19 two studies 
using peritoneal dialysis catheters used either Cefazolin or Vancomycin,18,28 
and a further solely using Sulbactam/Ampicillin.21 In one study, two patients 
with cirrhosis were commenced on long term antibiotic prophylaxis following 
development and successful treatment of bacterial peritonitis (BP).25 In these 
two cases,25 drainage catheters were not removed but left in situ throughout. 
Four studies reported the use of long term antibiotic prophylaxis (Ciprofloxacin 
or Norfloxacin);21,29,30,32 in one, a case series, prophylaxis was only used in 
the final two patients after review of the initial five cases,32 a second used 
prophylaxis only if there was a history of prior spontaneous bacterial 
peritonitis (SBP) or according to EASL guidelines,4,21 a third not defining in 
which population prophylactic antibiotics were used in.29 The remaining 
thirteen studies did not report the use of long-term prophylactic antibiotics18-
20,22-24,26-28,31,33-35 (Table 4).  
Place of management of ascites subsequent to device insertion 
In nine of the 18 studies, subsequent ascites drainage was exclusively at 
home, either by community nurses, participants themselves or care 
givers.18,21,23-25,28,31-33 Three reported ascites management in either a hospice 
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or participants’ home;19,30,35 in a further two, ascites management was either 
in a hospital outpatient setting, or the patients’ home;20,34 in one of these,20 a 
small proportion (three of the total mixed cohort of 27) were also managed in 
hospital when admitted for unrelated medical conditions (Table 4). Four 
studies did not state the place of further ascites management (Table 
4).22,26,27,29 One study reported two patients required further hospital 
admission for full drainage with intravenous albumin cover. In none of the 14 
studies which reported the place of subsequent drainage following PIPC 
insertion was hospital admission required for further ascites management.  
Specialist palliative care 
Of the 18 studies, 12 commented on PIPC performed as a palliative 
procedure (Table 4). 18-20,23,26,27,29-33,35 The remaining five used PIPC in both 
those who were and were not LT candidates.21,22,24,25,34 Only three studies 
alluded to input from specialist palliative care services.27,30,32  
Complications                                                                                                                   
Infectious and non-infectious complications in patients with ELSD are 
summarised in table 5. 
Table 5. 
Device related infections 
All but two studies reported cases of bacterial peritonitis (BP) occurring in 
patients with ESLD,26,29 however other infectious complications were not 
reported separately in this group. Complications, other than BP, have been 
described in those with ESLD where possible. 
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In six studies there were no episodes of BP in patients with 
ESLD.19,23,28,32,33,35 In our case series we reported organisms (Pseudomonas 
aeruginosa and Corynebacterium striatum) cultured from the PIPC in one 
case,32 however the clinical significance was uncertain. Nine studies reported 
cases of BP in ESLD,20-22,24,25,27,30,31,34 of these, three defined BP, only two 
studies stated ascitic fluid samples were taken when clinically indicated,27,34 
rather than as routine. Two episodes of BP occurred despite norfloxacin 
prophylaxis.21 Where PleurX™ PIPC were used in both abdominal ascites and 
hepatic hydrothoracies in ESLD, one case of BP was reported but not whether 
this was BP or bacterial empyema.22 An additional case of Escherichia coli 
sepsis was reported, described as a “catheter related infection”, without 
further information offered.22  
In one study with the highest prevalence of positive ascitic cultures (42%, 
n=14),24 further clarification sought from Reinglas et al confirmed that, in 
addition to sampling ascitic fluid in symptomatic patients, samples were also 
taken routinely throughout. It was unclear if these were taken from the PIPC 
or the abdomen. Organisms cultured were classified as typically associated 
with SBP in six (18%) and typically catheter-associated in 11 patients (33%).24 
Interpretation of routine ascitic fluid sampling in PIPC remains contentious, 
therefore it is unclear if all were true cases of BP.  
Rates of BP varied from 0% to 42% across individual studies with an overall 
combined rate of 17% (29/166). Excluding the 11 patients in Reinglas et al 
with catheter related organisms,24 the overall rate of BP was 12.7% (21 
patients). If the Reinglas study was excluded as an outlier,24 the overall rate of 
BP across the remaining 15 studies was 11% (15/133). Of these, four had the 
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PIPC removed and received antibiotics; eight were treated with antibiotics 
with PIPC left in situ; one was palliated as was end of life, in the remaining 
two, no subsequent management was described (Table 5).  
Two studies with a mixed cohort of malignant and non-malignant ascites 
reported 11 cases of BP but without differentiating between aetiology.26,29 
Cellulitis at catheter insertion site was reported in nine of 147 (6%) patients 
with ESLD.21,24,27,32 Four mixed cohort studies reported 11 patients with either 
cellulitis or “local infection”; without stating underlying aetiology, therefore not 
included in analysis.19,23,25,26 
Non-infectious complications 
Of the 142 patients with ESLD and PIPC where complications were reported 
separately in this group; minor transient hyponatraemia and rise in creatinine 
was reported in 16 (11%) and 12 (8%) respectively,21 leakage of ascites at 
exit sites 12 (8%),20,24,30,34 catheter occlusion in eight (6%),21,24,31,34 elevated 
serum urea in three (2%),24 accidental catheter displacement in two (1%),24,30 
others 3% (n=4) (acute kidney injury (AKI) n=1, haematoma n=1, hepatic 
encephalopathy (HE) n=1 and blood stained ascites post insertion 
n=1).20,24,32,34 (Table 5)  
Two bleeding complications (haematoma and blood stained ascites following 
catheter insertion) were reported and both self-resolved.24,34 Three with 
elevated serum urea were managed by reducing drainage episode 
frequency.24 The AKI case followed leakage of ascites at an access port 
site.20 The HE case had no clear precipitating cause, the authors felt likely 
representing ESLD progression.32 This was the same case of Pseudomonas 
aeruginosa and Corynebacterium striatum grown from the PIPC with 
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uncertain clinical significance, without other features of infection or empirical 
antibiotics leading to improvement.32 
In the eight studies with mixed RA aetiology, non-infectious complications 
were inconsistently reported in patients with cirrhosis, therefore included in 
table 5 where possible.19,20,23,25,28,33 Complications without RA aetiology 
defined were; 13 cases of ascites leakage at catheter insertion site,19,23,26 five 
unspecified catheter malfunctions,23 five occluded catheters, three were 
peritoneal ports with patency restored after administration of tissue 
plasminogen activator (tPA);19,26 four accidental catheter displacements,25,26 
two of groin pain,26 one abdominal pain with BP excluded25 and one port 
failure due to undiagnosed loculated ascites.20   
Patient and PIPC survival post insertion 
 
There was variable reporting of patient and PIPC survival, shown in table 4. 
Overall patient survival was limited, as expected in all aetiologies of RA. 
Where reported, median survival in ESLD varied between 29 days to six 
months,25,32 consistent with known median survival in this group.4 Median 
PIPC survival in ESLD ranged between six weeks to five months,28,35 in-
keeping with mean PleurX™ catheter survival in the malignant ascites NICE 
technology appraisal.13 
Quality of life assessments 
One study, Monsky,19 described the impact of PIPC on QoL using a 
questionnaire similar to the Chronic Liver Disease Questionnaire (CDLQ).36 
Assessments were conducted following PIPC insertion; home care and 
hospice nurses were also surveyed. Patients reported improvements in 
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mobility and daily activities, however a pre-PIPC questionnaire was not 
recorded for comparison. Nursing staff stated PIPC benefited QoL and 
advocated earlier placement.19  
No health economic assessments were undertaken. 
Discussion  
Main findings 
The use of PIPC in the management of malignant ascites is well 
established.13 In contrast, this is the first systematic review of PIPC in RA due 
to ESLD, summarising current international literature. It is not surprising that 
of the 18 studies identified, all but 12 were retrospective case series and/or 
cohort studies,22-32,35 the one randomised controlled trial (RCT) identified was 
well designed, however only enrolled one patient into each arm.18 Of the total 
176 patients with ESLD and RA who underwent PIPC insertion, technical 
success was 100%, rates of non-infectious complications generally low 
(<12%) and none life threatening. Rates of the most feared complication i.e. 
BP (12.7%) were also not unacceptably high considering prophylactic long-
term antibiotics were only used in 21/169 (12%) patients.21,29,30,32,37 It is 
unclear if all reported cases of BP were true BP or due to colonisation, 
however these rates fall within that expected in ESLD (up to 14% in more 
recent data, 15%-19% in older data).5,38 In patients undergoing peritoneal 
dialysis (PD), PD peritonitis is an accepted complication.39 Current 
recommendations state rates should not exceed 0.5 episodes per year.39 
However, this cannot be extrapolated to PIPC in ESLD, this being a largely 
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palliative cohort focussing on symptom relief. This could explain why in some 
studies, development of BP did not mandate PIPC removal.21,25,34  
Limitations 
While the initial data on safety and efficacy of PIPC in ESLD and RA are 
encouraging, this needs to be interpreted with caution. Our systematic review 
describes PIPC outcomes in ESLD from heterogeneous, poor quality studies 
with small sample sizes, using a variety of different indwelling catheters, 
hence making direct comparison impossible. Data provided on the severity of 
liver disease (Child Pugh, MELD), patient and catheter related survival and 
prior history of spontaneous bacterial peritonitis (SBP) were limited and 
inconsistent. Prophylactic antibiotics were used in only three (12%) 
studies.21,30,32 In the study addressing QoL, interpretation of results were 
hampered by suboptimal design.19 Finally, none attempted to assess health 
economic outcomes of PIPC in ESLD and RA. 
What this study adds 
There is increasing burden from CLD deaths, representing the third 
commonest cause of premature death in the UK.1 Most individuals with ESLD 
develop ascites which, in the absence of LT, is associated with a limited life 
expectancy.4,6 Ascites causes physical and psychological symptoms, 
significantly impacting QoL.4,12 The development of RA further limits 
prognosis, its management in the majority remains palliative, as only a small 
proportion are successfully transplanted.4,10 LVP remains the commonest 
palliative intervention in RA, however offers limited symptom improvement,12 
necessitates repeated hospitalisations and can be associated with post-
paracentesis circulatory dysfunction, HE, and rarely other complications.40  
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Further interventions for RA include invasive procedures such as 
peritoneovenous shunts, now virtually obsolete due to complications, the 
ALFApump and TIPS.4 Meta-analyses comparing TIPS with LVP reported 
TIPS to be more effective in reducing ascites recurrence, however with a 
greater incidence of HE (prevalence 15%-61%); with conflicting survival 
outcome data.4 In one small retrospective study (n=10) of palliative TIPS for 
RA +/- hepatic hydrothorax in ESLD, 50% developed HE with more than half 
subsequently dying within three months.41  
The ALFApump involves an implantable device pumping ascites from the 
peritoneal cavity into the bladder.42 Consistent with the initial European 
multicentre safety and efficacy study and the multicentre RCT,43,44 recent 
studies have corroborated complication rates of infections (11%-56%),45,46 
renal dysfunction (21%-67%),45-47 device deficiency including catheter 
occlusion (9%-33%)45,46 and explantation rates of up to 30%.46 Recent NICE 
guidance on the ALFApump advises use only with ‘special arrangements’ 
and in research settings.49 
TIPS and the ALFApump, therefore, may be less appropriate as palliative 
interventions. Focus on interventional procedures may be at the expense of 
integrated holistic palliative care, symptom management and supporting 
discussions to establish future wishes.48  
With an increasing burden from CLD and lack of effective palliative options for 
RA, the absence of data on PIPC is surprising.10 PIPC are accepted 
management in recurrent malignant ascites, the NICE technology appraisal 
concluding PIPC clinically effective, having low complication rates, could 
improve QoL and were less costly than LVP.13 A study using PleurX™ PIPC 
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in malignant ascites reported improvement in dyspnoea within two weeks of 
insertion.50 Other potential benefits include patient autonomy and community-
based care, allowing remaining life to be spent at their preferred place of 
residence.  
Defining the final phase of illness in non-malignant life-limiting diseases can 
be challenging, though RA is a valuable prognostic guide in ESLD.4 Despite 
this and the fact that the majority will be ineligible for LT, strategies for 
palliative management in ESLD are not well defined or integrated.5,9,10 As 
complex EoLC needs are often present, management remains mainly within 
secondary care with over 70% dying in hospital.2,51 In England, despite 
pockets of excellence,52 little specialist palliative care is provided in hospices 
or the community, despite services being available.2,3  
Only a small proportion (7.5%) of patients with cirrhosis receive an out-patient 
palliative care consultation despite symptoms or disease severity; the only 
predictor of palliative care referral being concomitant hepatocellular 
carcinoma (HCC).53 An early palliative care intervention in patients referred for 
LT assessment reported 50% of moderate to severe symptoms significantly 
improved.54 
Local data in those with RA undergoing LVP showed that only 33% overall 
were referred to specialist palliative care despite a minority, 12%, being listed 
for LT.9  A survey amongst UK consultants suggested potential contributors 
being inadequate understanding of the fluctuating disease trajectory and 
discomfort with the subject of palliative care in ESLD.55  
There have been calls to improve the quality of care for those living with and 
dying from ESLD with greater and timelier integration of palliative care.3 This 
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and the initial positive experiences of PIPC, prompted our group to obtain 
National Institute for Health Research (NIHR) funding for a prospective 
feasibility RCT comparing palliative PIPC (Rocket®) with LVP in ESLD 
(REDUCe Study, ISRCTN 30697116).56 This mixed methods study has 
collected clinical, qualitative, patient reported and health economic data to 
inform a potential future definitive RCT.56 Initial results are encouraging.57 
Although being a UK based trial, the implications could be international, the 
ultimate aim being to improve EoLC and contribute to the understanding of 
palliative care needs of those with RA due to ESLD. 
Conclusions  
This systematic review has described the use and preliminary safety and 
efficacy data of PIPC in RA and ESLD, with only two further hospitalisations 
for ascites drainage required. Though the prevalence of peritonitis was no 
higher than that seen in an ESLD population, the lack of well-designed studies 
impacts the pooled analysis. This underlines the need for well-designed RCT 
to assess the safety and efficacy of PIPC in RA in ESLD, aiming to improve 
QoL. This will contribute to a growing body of international evidence to 
support those with ESLD and RA in receiving more equitable palliative and 
EoLC care as in other non-malignant life-limiting diseases. 
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Tables 
 
Databases Date initial search 
performed 
Date repeat 
search performed 
Medline (HDAS) (1946 to date of 
search)  
7.12.15 13.03.18 
Medline (OVID) (1946 to date of 
search)  
3.12.15 13.03.18 
Embase (HDAS) (1974 to date of 
search)  
4.12.15 13.03.18 
Embase (OVID) (1974 to date of 
search)  
7.12.15 13.03.18 
CINAHL (HDAS) (1981 to date of 
search)  
8.12.15 13.03.18 
Cochrane Database of Systematic 
Reviews  
8.12.15 13.03.18 
Table 1 Databases used in search 
 
 
 
 
 
 
Keywords 
Ascit*, “refractory ascit*”, “resistant ascit*”, (refractory AND ascit*), (resistant AND ascit*), 
“ascitic drain*” (ascitic AND drain*), “diuretic intolerant ascit*”, paracentesis, “palliative 
medicine”, palliat*, “terminal care”, terminal*, “palliative care”, (palliative AND medicine), 
(palliative AND care), (terminal AND care), “end of life care”, (end AND of AND life AND care), 
(hospice AND care), hospice*. 
MeSH Terms 
ASCITES, ASCITIC FLUID, PORTAL HYPERTENSION, TRANSJUGULAR INTRAHEPATIC 
PORTOSYSTEMIC SHUNT, PARACENTESIS, TERMINAL CARE, TERMINALLY ILL, 
PALLIATIVE CARE, PALLIATIVE MEDICINE, HOSPICE AND PALLIATIVE CARE NURSING, 
HOSPICE CARE, HOSPICES  
Table 2 Keywords and MeSH Terms 
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Inclusion criteria Exclusion criteria 
Adult participants (≥18 years of age) Paediatric participants (<18 years of 
age) 
PIPC for recurrent drainage of ascites 
secondary to liver disease 
Animal studies 
English language articles Shunting devices (including 
peritoneovenous, TIPS) and 
ALFApump 
 Manuscripts reporting solely on 
malignant ascites and/or patients 
undergoing chemotherapy 
Table 3 Inclusion and exclusion criteria 
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Author, 
year 
(country), 
Design 
Population 
and 
drainage 
site/ 
Number of 
cases with 
cirrhosis 
related 
ascites 
 
Type of 
PIPC/ 
Place of 
insertion 
Prophylacti
c antibiotics 
Palliative or 
non-
palliative 
Place of 
further 
ascites 
manageme
nt 
Patient 
survival 
post PIPC 
insertion/ 
Duration 
PIPC 
remained 
in situ 
Ahmed, 
201818 
(Canada) 
Prospective 
pilot single 
centre 
randomised 
controlled 
trial project 
report 
Cirrhosis; 
Peritoneal 
n=1  
(1 patient 
in 
peritoneal 
dialysis 
catheter 
arm, 1 in 
standard 
care arm) 
 
Tunnelled 
peritoneal 
dialysis 
catheters 
Interventio
nal 
nephrologi
st 
During 
insertion 
procedure 
only - 
Cefazolin 
or 
Vancomyci
n 
Non-LT 
candidates; 
Palliative 
care not 
mentioned 
Home (self-
drainage by 
patient) 
Reported 
the patient 
completed 
study 
follow up 
period of 6 
months/ 
Not 
reported 
Corrigan et 
al, 201827 
(UK) 
Retrospecti
ve cohort 
study  
(Conferenc
e poster) 
Cirrhosis; 
Peritoneal 
and 
pleural 
n=24  
(total 29 
catheters 
in 28 
patients 
with 
ascites 
and 
hepatic 
hydrothora
x – not 
distinguish
ed in 
abstract) 
 
Unspecifie
d tunnelled 
indwelling 
peritoneal 
catheter 
Interventio
nal 
radiologist
s 
None Non-LT 
candidates 
24 patients 
referred to 
palliative 
care 
Not stated 6 and 12 
month 
survival 
available 
on 24 
patients; 
50% and 
25% 
respectivel
y/ 
Not 
reported 
Hingwala et 
al, 201728 
(Canada) 
Retrospecti
ve cohort 
study 
Mixed; 
Peritoneal 
n=8 
Tunnelled 
peritoneal 
dialysis 
catheters 
Interventio
nal 
nephrologi
st under 
ultrasound 
and 
fluoroscopi
c guidance 
 
During 
insertion 
procedure 
only - 
Cefazolin 
or 
Vancomyci
n 
Not stated Home (self-
drainage by 
patient 
Median 
catheter 
survival 
146 days 
(interquartil
e range 
33.5-1039 
days) 
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Author, 
year 
(country), 
Design 
Population 
and 
drainage 
site/ 
Number of 
cases with 
cirrhosis 
related 
ascites 
Type of 
PIPC/ 
Place of 
insertion 
Prophylacti
c antibiotics 
Palliative or 
non-
palliative 
Place of 
further 
ascites 
manageme
nt 
Patient 
survival 
post PIPC 
insertion/ 
Duration 
PIPC 
remained 
in situ 
Imler et al, 
201222 
(USA) 
Retrospecti
ve cohort 
study  
(Conferenc
e poster) 
Cirrhosis; 
Peritoneal 
and 
pleural 
n=16  
(26 total 
ascites 
and 
hepatic 
hydrothora
x) 
PleurX™ 
Interventio
nal 
radiology 
database 
(insertion 
method 
not 
mentioned
) 
None Patients on 
LT list as 
well as 
palliative. 
No mention 
of palliative 
care 
Not stated 30 and 90 
day 
mortality 
after 
device 
insertion: 
30.8% and 
61.5% 
respectivel
y/ 
Not 
reported 
 
 
Knight et al, 
201726 
(USA)  
Retrospecti
ve cohort 
study 
Mixed; 
Peritoneal 
n=3 
PleurX™ 
Interventio
nal 
radiologist
s - 
ultrasound 
guidance 
 
None Palliative 
intent but 
no specific 
palliative 
care input 
mentioned 
 
Not stated 
however 
stated no 
concomitant 
LVP 
required 
Median 
survival 
from 
insertion to 
death 85 
days 
Kriese et al, 
201330 
(UK) 
Retrospecti
ve case 
series 
(Conferenc
e poster) 
Cirrhosis; 
Peritoneal  
n=4 
PleurX™ 
Not stated 
Ciprofloxaci
n 
Palliative 
intent but 
no specific 
palliative 
care input 
mentioned 
Home/ 
hospice 
Not 
reported/ 
Catheter in 
situ for a 
median of 
30 days 
(20 – 50) 
before 
removal or 
death 
 
 
Kundu et 
al, 201231 
(USA) 
Retrospecti
ve case 
series 
(Conferenc
e poster) 
 
Cirrhosis; 
Peritoneal  
n=12 
Unspecifie
d tunnelled 
indwelling 
peritoneal 
catheter 
Interventio
nal 
radiologist
s 
 
 
None Non-LT 
candidates; 
Palliative 
care not 
mentioned 
Home (self-
drainage by 
patient) 
Not 
reported/ 
Median 
duration of 
catheter 
function 2 
months 
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Author, 
year 
(country), 
Design 
Population 
and 
drainage 
site/ 
Number of 
cases with 
cirrhosis 
related 
ascites 
 
Type of 
PIPC/ 
Place of 
insertion 
Prophylacti
c antibiotics 
Palliative or 
non-
palliative 
Place of 
further 
ascites 
manageme
nt 
Patient 
survival 
post PIPC 
insertion/ 
Duration 
PIPC 
remained 
in situ 
Lungren et 
al, 201323 
(USA) 
Retrospecti
ve cohort 
study 
Mixed; 
Peritoneal  
n=7 
PleurX™ 
Interventio
nal 
radiologist
s - 
ultrasound 
guidance 
During 
insertion 
procedure 
only - 
Cefazolin 
or 
Clinamycin 
No mention 
of palliative 
care other 
than some 
overall 
discharged 
to USA 
hospice 
care* 
Home – 
patients or 
carers/hospi
ce 
Not 
reported/ 
Mean 
catheter 
survival 60 
days (0-
796 days), 
(11,903 
cumulative 
catheter 
days) 
 
 
 
Macken et 
al, 201632 
(UK) 
Retrospecti
ve case 
series 
Cirrhosis; 
Peritoneal  
n=7 
Rocket® 
Ultrasound 
guidance, 
(gastroent
erology) 
physicians 
Ciprofloxaci
n/ 
Norfloxacin 
after review 
of first 5 
cases 
Non-LT 
candidates, 
reviewed by 
palliative 
care team 
Home 
(district 
nurse) 
Median 
patient 
survival 29 
days  
(8-219)/ 
Not 
reported 
 
 
Monsky et 
al, 200919 
(USA) 
Prospective 
cohort 
study with 
QoL 
assessment 
Mixed; 
Peritoneal 
and 
pleural  
n=2 
(further 1 
with 
hepatic 
hydrothora
x) 
Peritoneal 
and pleural 
catheters 
with 
percutane
ous 
access 
ports  
(Celsite 
DRAINAP
ORT) 
Interventio
nal 
radiologist
s – 
ultrasound 
and 
fluoroscopi
c guidance 
 
 
During 
insertion 
procedure 
only - 
Cefazolin 
and 
Metronidaz
ole 
No mention 
palliative 
care except 
USA 
hospice 
care* 
Hospice/ 
home care 
nurses 
Not 
reported/ 
Not 
reported 
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Author, 
year 
(country), 
Design 
Population 
and 
drainage 
site/ 
Number of 
cases with 
cirrhosis 
related 
ascites 
 
 
Type of 
PIPC/ 
Place of 
insertion 
Prophylacti
c antibiotics 
Palliative or 
non-
palliative 
Place of 
further 
ascites 
manageme
nt 
Patient 
survival 
post PIPC 
insertion/ 
Duration 
PIPC 
remained 
in situ 
Po et al, 
199633 
(USA) 
Prospective 
case series 
(Conferenc
e poster) 
 
 
 
Mixed; 
Peritoneal  
n=1 
Peritoneal 
dialysis 
(Tenckhoff
) catheter 
Surgical 
insertion 
None No mention 
palliative 
care input. 
“Terminally 
ill patients” 
suggests 
palliative 
intervention 
Home, by 
patient 
Mean 
duration of 
survival 6 
months/ 
Not 
reported 
Reinglas et 
al, 201624 
(Canada) 
Retrospecti
ve cohort 
study 
Cirrhosis; 
Peritoneal  
n=33 
PleurX™ 
Tunnelled 
indwelling 
peritoneal 
catheter 
Ultrasound 
guidance. 
Not stated 
by whom 
None LT 
candidates 
and non-LT 
candidates 
Described 
as palliative 
manageme
nt but not 
palliative 
care input 
 
 
 
 
Home care 
nurses 
Not 
reported/ 
Median 
duration 
117.5 days 
Reisfield et 
al, 200335 
(USA) 
Case report 
(total of 5 
cases) 
Cirrhosis; 
Peritoneal  
n=5 
PleurX™ 
Tunnelled 
indwelling 
peritoneal 
catheter 
Ultrasound 
guidance, 
not stated 
by whom 
None Non-LT 
candidates. 
USA 
hospice 
care* 
mentioned 
but not 
integrated 
palliative 
care 
Hospice 
then at 
home, 
initially by 
hospice 
nurse then 
by patient 
and family 
member 
Mean 
duration of 
catheters 
in situ was 
more than 
6 weeks – 
all 
remained 
in situ until 
the time of 
death/ 
Mean 
duration 
more than 
6 weeks 
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Author, 
year 
(country), 
Design 
Population 
and 
drainage 
site/ 
Number of 
cases with 
cirrhosis 
related 
ascites 
 
 
 
Type of 
PIPC/ 
Place of 
insertion 
Prophylacti
c antibiotics 
Palliative or 
non-
palliative 
Place of 
further 
ascites 
manageme
nt 
Patient 
survival 
post PIPC 
insertion/ 
Duration 
PIPC 
remained 
in situ 
Riedel et al, 
201829 
(Denmark) 
Retrospecti
ve cohort 
study with 
matched 
cohorts 
  
Mixed; 
Peritoneal 
n=7 
PleurX™ 
Tunnelled 
indwelling 
peritoneal 
catheter 
Trained 
physicians,  
x-ray 
guided 
Cefuroxime 
during 
insertion 
procedure 
Reported 
16 patients 
received 
further 
prophylacti
c 
Ciprofloxaci
n but not 
which 
cohort 
 
 
 
 
Non-LT 
candidates; 
Palliative 
care not 
mentioned 
Not stated Mean 
survival 
200 days 
Rosenblum 
et al, 
200134 
(USA) 
Prospective 
case series  
Cirrhosis; 
Peritoneal  
n=9 
Peritoneal 
catheter 
with 
access 
port 
(modified 
venous 
access 
ports) 
Interventio
nal 
radiologist
s under 
ultrasound 
and 
fluoroscopi
c guidance 
 
 
 
 
 
 
 
During 
insertion 
procedure 
only - 
Cefazolin 
LT 
candidates 
and 
supportive 
care. 
No mention 
of palliative 
care input 
Nurse in 
gastroenter
ology 
outpatient 
clinic and 2 
in 
community 
by visiting 
nurse 
Not 
reported/ 
Mean port 
patency 
was at 
least 255 
days with a 
total of 
1557 port 
days 
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Author, 
year 
(country), 
Design 
Population 
and 
drainage 
site/ 
Number of 
cases with 
cirrhosis 
related 
ascites 
 
 
Type of 
PIPC/ 
Place of 
insertion 
Prophylacti
c antibiotics 
Palliative or 
non-
palliative 
Place of 
further 
ascites 
manageme
nt 
Patient 
survival 
post PIPC 
insertion/ 
Duration 
PIPC 
remained 
in situ 
Savin et al, 
200520 
(USA) 
Prospective 
cohort 
study 
Mixed; 
Peritoneal  
n=4 
Peritoneal 
catheter 
with 
access 
port  
(Port-a-
cath 
peritoneal 
implantabl
e access 
system) 
Interventio
nal 
radiologist
s under 
ultrasound 
and 
fluoroscopi
c guidance 
 
 
 
During 
insertion 
procedure 
only - 
Cefazolin 
Palliative 
manageme
nt. Palliative 
care input 
not 
mentioned 
Hospital 
outpatients 
and as 
inpatient, as 
well as at 
home with 
visiting 
nurses 
Not 
reported/ 
1810 port 
days (in 27 
patients in 
the total 
mixed 
cohort) 
 
Semadeni 
et al, 
201525 
(Switzerlan
d) 
Retrospecti
ve cohort 
study 
(Conferenc
e poster) 
Mixed; 
Peritoneal  
n=9 
PleurX™ 
Tunnelled 
indwelling 
peritoneal 
catheter 
Gastroente
rology 
consultant 
under 
ultrasound 
guidance 
During 
insertion 
procedure - 
Ceftriaxone
. Two 
cases 
received 
prophylaxis 
with 
Norfloxacin 
and 
Ciprofloxaci
n, 
respectively 
after 
developed 
and treated 
for BP 
 
 
 
LT 
candidates 
and non-LT 
candidates 
Palliative 
care not 
mentioned 
Home (by 
patient) 
Mean 
survival in 
patients 
with 
cirrhosis 
192 days/ 
Mean 
catheter 
survival in 
patients 
with 
cirrhosis 
111 days 
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Author, 
year 
(country), 
Design 
Population 
and 
drainage 
site/ 
Number of 
cases with 
cirrhosis 
related 
ascites 
Type of 
PIPC/ 
Place of 
insertion 
Prophylacti
c antibiotics 
Palliative or 
non-
palliative 
Place of 
further 
ascites 
manageme
nt 
Patient 
survival 
post PIPC 
insertion/ 
Duration 
PIPC 
remained 
in situ 
Solbach et 
al, 201721 
(Germany) 
Prospective 
cohort 
study 
Cirrhosis; 
Peritoneal  
n=24 
 
PleurX™ 
Tunnelled 
indwelling 
peritoneal 
catheter 
Ultrasound 
guidance. 
Not stated 
by whom 
During 
insertion 
procedure 
Sulbactam/
Ampicillin. 
Norfloxacin 
15/24 63% 
- in prior 
history of 
SBP and 
defined risk 
factors as 
per EASL 
guidelines 
LT 
candidates 
and non-LT 
candidates 
Palliative 
care not 
mentioned 
Home (by 
patient) 
16/24 67% 
remained 
in situ until 
death 
(mean 
97.6+/-
51.4 days).  
Five 
patients 
listed and 
underwent 
LT/ 
Mean 
indwelling 
catheter 
time 
83.2+/- 
54.3 days       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 4 Summary of studies included in the systematic review 
USA = United States of America, UK = United Kingdom, Mixed = malignant and cirrhotic ascites 
as well as ascites due to other causes, QoL = quality of life, LT = liver transplant, LVP = large 
volume paracentesis, BP = bacterial peritonitis, SBP = spontaneous bacterial peritonitis. *It is 
worth noting that in the USA that phrase “Hospice care” is usually interpreted as only being 
instituted late in disease (on average 14 days before death for all diseases). This differs from UK 
interpretation where “Hospice care” can be instituted synchronously with active/secondary care.        
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Author, year 
(country), 
Number of cases 
(n) 
Bacterial peritonitis   Cellulitis Non-infectious 
complications 
Ahmed 201818 
(Canada) 
n=1 
 
Not reported Not reported Not reported 
Corrigan et al, 
201827 
(UK) 
n=24 
3 (12.5%) received 
antibiotics after 
admission with 
abdominal pain, 2 
having positive 
ascitic taps 
3 (11%) with skin site 
erythema and positive 
skin swabs – not 
reported if received 
antibiotics  
Not reported if 
occurred in abdominal 
or pleural drains 
 
3 leaking insertion 
sites (not reported if 
pleural or 
abdominal) 
1 catheter blocked 
and subsequently 
removed 
Hingwala et al, 
201728 
(Canada) 
n=8 
None None None 
Imler et al, 201222 
(USA) 
n=16 
1 (6%) – not 
specified if BP or 
spontaneous 
bacterial empyema 
None None 
Kriese et al, 201330 
(UK) 
n=4 
1 (25%), non-fatal, 
catheter removed 
and replaced 
None 1 (25%)accidental 
removal of catheter, 
1 (25%) leakage of 
ascites at insertion 
site (same as 
patient as 
developed BP) 
 
Kundu et al, 201231 
(USA) 
n=12 
2 (17%), catheters 
removed, treated 
with antibiotics 
None 1 (8%) obstructed 
drain, re-sited 
Lungren et al, 
201323 
(USA) 
n=7 
None 3 (but included 
patients with mixed 
aetiology for RA and 
aetiology not 
specified) 
5 “catheter 
malfunction” 
unspecified, 4 
ascites leakage at 
incisional site 
(requiring suture 
placement) (but 
included patients 
with mixed 
aetiology for RA 
and aetiology not 
specified) 
 
Macken et al, 
201632 
(UK) 
n=7 
None 2 (29%) one treated 
with antibiotics, one 
drain removed and re-
sited after treatment 
 
HE of unclear 
cause 
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Author, year 
(country), 
Number of cases 
(n) 
Bacterial peritonitis   Cellulitis Non-infectious 
complications 
Monsky et al, 
200919 
(USA) 
n=2 
None 3 (but included 
patients with mixed 
aetiology for RA and 
aetiology not 
specified) 
3 temporary 
occlusions (patency 
restored using tPA 
infusion), 3 self-
limiting ecchymosis, 
1 leakage of ascites 
(but included 
patients with mixed 
aetiology for RA 
and aetiology not 
specified) 
Po et al, 199633 
(USA) 
n=1 
None None – none reported 
in mixed cohort 
None – none 
reported in mixed 
cohort 
Reinglas et al, 
201624 
(Canada) 
n=33 
14 (42%) with 
positive routine 
peritoneal fluid 
cultures; 6 with 
typical SBP 
organisms  
6 catheters removed, 
all patients 
successfully treated 
with antibiotics 
3 treated with 
antibiotics – no 
mention if catheter 
removed 
7 (21%) ascites 
leakage at PIPC 
site – 5 resolved, 1 
PIPC removed, 1 
further sutures 
around PIPC, 1 
eventual PIPC 
removal due to 
persistent leakage.  
3 (9%) rise in urea  
3 (9%) PIPC 
occlusions (1 
patency restored 
using tPA, 2 
successful PIPC 
replacement) 
1 (3%)accidental 
catheter 
displacement 
1 (3%) haematoma, 
resolved 
 
Reisfield et al, 
200335 
(USA) 
n=5 
None None None 
Rosenblum et al, 
200134 
(USA) 
n=9 
3 (33%), 1 treated 
with intravenous 
antibiotics, 1 port 
removed, 1 palliated 
(no active treatment) 
None 3 (33%) ascites 
leakage at PIPC 
site - patient 
subsequently 
developed BP 
1 (11%) PIPC 
occlusion  
1 (11%) blood 
stained ascites 
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Author, year 
(country), 
Number of cases 
(n) 
Bacterial peritonitis   Cellulitis Non-infectious 
complications 
Savin et al, 200520 
(USA) 
n=4 
1 (25%), 
management not 
reported mixed 
cohort but specified 
as being in ESLD 
patient 
None – none reported 
in mixed cohort 
1 (4% of total mixed 
cohort) leakage at 
site - in ESLD 
patient - same 
patient who 
developed BP 
1 (4% of total mixed 
cohort) AKI – 
specified as being 
in ESLD patient 
1 (4% of total mixed 
cohort) loculated 
ascites recognised 
after PIPC insertion 
Semadeni et al, 
201525 
(Switzerland) 
n=9 
2 (22%), treated with 
antibiotics, catheters 
remained in situ, 
subsequently started 
prophylactic 
antibiotics 
2 “local infection” (but 
included patients with 
mixed aetiology for RA 
and aetiology not 
specified) 
2 (4% of total mixed 
cohort) accidental 
catheter dislocation 
1 intermittent 
abdominal pain with 
BP excluded (but 
included patients 
with mixed 
aetiology for RA 
and aetiology not 
specified) 
Solbach et al, 
201721 
(Germany) 
n=24 
2 (8%), treated 
successfully with 
antibiotics  
Developed despite 
Norfloxacin 
prophylaxis 
1 (4%) – same patient 
developed BP 
16 (67%) minor 
transient 
hyponatraemia at 
week 4 
12 (50%) small 
transient increase in 
creatinine at week 
12 
2 (13%) PIPC 
occlusion – 
resolved with 
flushing 
1 (4%) complete 
PIPC occlusion – 
further PIPC re-
sited 
1 abdominal pain 
with BP excluded – 
resolved with 
placement of 
shorter catheter   
 
 
Table 5 Infectious and non-infectious complications in patients with ESLD and PIPC 
USA = United States of America, UK = United Kingdom, Mixed = malignant and cirrhotic 
ascites as well as ascites due to other causes, QoL = quality of life, SBP = spontaneous 
bacterial peritonitis, AKI = acute kidney injury, tPA = Tissue plasminogen activator  
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